LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Fundus albipunctatus: review of the literature and report of a novel RDH5 gene mutation affecting the invariant tyrosine (p.Tyr175Phe).

    Skorczyk-Werner, Anna / Pawłowski, Przemysław / Michalczuk, Marta / Warowicka, Alicja / Wawrocka, Anna / Wicher, Katarzyna / Bakunowicz-Łazarczyk, Alina / Krawczyński, Maciej R

    Journal of applied genetics

    2015  Volume 56, Issue 3, Page(s) 317–327

    Abstract: Fundus albipunctatus (FA) is a rare, congenital form of night blindness with rod system impairment, characterised by the presence of numerous small, white-yellow retinal lesions. FA belongs to a heterogenous group of so-called flecked retina syndromes. ... ...

    Abstract Fundus albipunctatus (FA) is a rare, congenital form of night blindness with rod system impairment, characterised by the presence of numerous small, white-yellow retinal lesions. FA belongs to a heterogenous group of so-called flecked retina syndromes. This disorder shows autosomal recessive inheritance and is caused mostly by mutations in the RDH5 gene. This gene encodes the enzyme that is a part of the visual cycle, the 11-cis retinol dehydrogenase. This study is a brief review of the literature on FA and a report of the first molecular evidence for RDH5 gene mutation in a Polish patient with this rare disorder. We present a novel pathogenic RDH5 gene mutation in a 16-year-old female patient with symptoms of night blindness. The patient underwent ophthalmological examinations, including colour vision testing, fundus photography, automated visual field testing, full-field electroretinography (ERG) and spectral optical coherent tomography (SOCT). The patient showed typical FA ERG records, the visual field was constricted and fundus examination revealed numerous characteristic, small, white-yellowish retinal lesions. DNA sequencing of the RDH5 gene coding sequence (exons 2-5) enabled the detection of the homozygous missense substitution c.524A > T (p.Tyr175Phe) in exon 3. This is the first report of RDH5 gene mutation that affects the invariant tyrosine, one of the most conserved amino acid residues in short-chain alcohol dehydrogenases/reductases (SDRs), crucial for these enzymes' activity. The location of this substitution, together with its predicted influence on the protein function, indicate that the p.Tyr175Phe mutation is the cause of FA in our patient.
    MeSH term(s) Adolescent ; Alcohol Oxidoreductases/genetics ; Amino Acid Sequence ; DNA Mutational Analysis ; Female ; Humans ; Male ; Molecular Sequence Data ; Night Blindness/genetics ; Pedigree ; Poland ; Retinal Diseases/genetics ; Tyrosine/genetics
    Chemical Substances Tyrosine (42HK56048U) ; Alcohol Oxidoreductases (EC 1.1.-) ; retinol dehydrogenase 5 (EC 1.1.1.105)
    Language English
    Publishing date 2015-08
    Publishing country England
    Document type Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1235302-4
    ISSN 2190-3883 ; 1234-1983
    ISSN (online) 2190-3883
    ISSN 1234-1983
    DOI 10.1007/s13353-015-0281-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Ghrelin: a recently discovered gut-brain peptide (review).

    Lazarczyk, Marta Alicja / Lazarczyk, Maciej / Grzela, Tomasz

    International journal of molecular medicine

    2003  Volume 12, Issue 3, Page(s) 279–287

    Abstract: In the 70s, several new, both peptidyl and non-peptidyl, derivatives that stimulate and amplify pulsatile growth hormone (GH) secretion, independently from growth hormone releasing hormone (GHRH), were synthesized. The family of these molecules have been ...

    Abstract In the 70s, several new, both peptidyl and non-peptidyl, derivatives that stimulate and amplify pulsatile growth hormone (GH) secretion, independently from growth hormone releasing hormone (GHRH), were synthesized. The family of these molecules have been named growth hormone secretagogues (GHSs). The subsequent discovery of the natural receptor for GHSs (GHS-R) suggested existence of a new regulatory system, participating in GH secretion control. Three years later a natural ligand for GHS-R was identified and was designated 'ghrelin'. Subsequently, it has been found that ghrelin exerts pleiotropic activity. It influences not only GH release but also food intake, function of gastrointestinal tract and cardiovascular system, sleep patterns as well as cancer proliferation. The current knowledge on ghrelin, its structure and function, is reviewed in this article.
    MeSH term(s) Brain/metabolism ; Cardiovascular System/metabolism ; Cell Division/physiology ; Digestive System/metabolism ; Eating/physiology ; Ghrelin ; Growth Hormone/metabolism ; Neoplasms/metabolism ; Peptide Hormones/blood ; Peptide Hormones/chemistry ; Peptide Hormones/physiology
    Chemical Substances Ghrelin ; Peptide Hormones ; Growth Hormone (9002-72-6)
    Language English
    Publishing date 2003-09
    Publishing country Greece
    Document type Journal Article ; Review
    ZDB-ID 1444428-8
    ISSN 1107-3756
    ISSN 1107-3756
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Pentoxifylline promotes development of murine colon adenocarcinoma-derived metastatic tumors in liver.

    Grzela, Tomasz / Lazarczyk, Maciej / Niderla, Justyna / Golab, Jakub / Lazarczyk, Marta Alicja / Skopinski, Piotr

    Oncology reports

    2003  Volume 10, Issue 6, Page(s) 1805–1809

    Abstract: Pentoxifylline is commonly used in the treatment of peripheral vascular diseases. It improves microcirculatory flow and tissue perfusion. Moreover, pentoxifylline displays some immunomodulatory properties that presumably might affect the anticancer ... ...

    Abstract Pentoxifylline is commonly used in the treatment of peripheral vascular diseases. It improves microcirculatory flow and tissue perfusion. Moreover, pentoxifylline displays some immunomodulatory properties that presumably might affect the anticancer response. Therefore, the aim of the present study was to evaluate the influence of pentoxifylline on tumor development. Balb/c mice were injected with murine colon adenocarcinoma C-26 cells intravenously, into the vena portae, and divided into two groups. Mice from the experimental groups received daily intraperitoneal injections of pentoxifylline (30 mg/kg) while the controls were injected with 0.9% NaCl. Two weeks after C-26 cell inoculation mice were sacrificed and autopsy was performed. It was found that the livers of control animals revealed only several small tumor foci, whereas the livers of pentoxifylline-treated mice displayed numerous cancerous outgrowths. The mean liver weight in pentoxifylline group was 2.21+/-0.62 g as compared to 1.36+/-0.15 g in controls (P=0.004). Moreover, the influence of pentoxifylline on murine and human cell line proliferation in vitro was evaluated. It has been observed that pentoxifylline, at pharmacologically achievable concentrations, stimulated the proliferation of murine (C-26) and human (CaSki, U-937) cell lines. However, it did not stimulate human melanoma (WM-35) cell proliferation. Since there has been no evidence so far that pentoxifylline may promote tumor progression, it is still considered to be a safe drug. Moreover, some beneficial properties of pentoxifylline, which could be useful in cancer treatment, have been reported and a few clinical trials with oncological patients have been performed. Surprisingly, our study revealed that pentoxifylline significantly promoted C-26-derived metastatic tumor growth in liver. Although this model might be unique in its sensitivity to tumor-promoting effects of pentoxifylline, it cannot be excluded that similar effects might occur in some cases of tumors developing in humans. Such effects could be relevant, since the stimulatory influence of pentoxifylline on proliferation does not appear to be species- or tissue-specific.
    MeSH term(s) Adenocarcinoma/drug therapy ; Adenocarcinoma/pathology ; Animals ; Cell Division ; Cell Line, Tumor ; Colonic Neoplasms/drug therapy ; Colonic Neoplasms/pathology ; Coloring Agents/pharmacology ; Dose-Response Relationship, Drug ; Female ; Free Radical Scavengers/pharmacology ; Humans ; Liver/pathology ; Liver Neoplasms/drug therapy ; Liver Neoplasms/pathology ; Mice ; Mice, Inbred BALB C ; Neoplasm Metastasis ; Neoplasm Transplantation ; Pentoxifylline/pharmacology ; Tetrazolium Salts/pharmacology ; Thiazoles/pharmacology ; U937 Cells
    Chemical Substances Coloring Agents ; Free Radical Scavengers ; Tetrazolium Salts ; Thiazoles ; thiazolyl blue (EUY85H477I) ; Pentoxifylline (SD6QCT3TSU)
    Language English
    Publishing date 2003-11
    Publishing country Greece
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1222484-4
    ISSN 1791-2431 ; 1021-335X
    ISSN (online) 1791-2431
    ISSN 1021-335X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Influence of pentoxifylline on natural cytotoxicity and expression of granzymes and PI-9, a specific granzyme B inhibitor.

    Lazarczyk, Maciej / Dziunycz, Piotr / Niderla, Justyna / Milewski, Lukasz / Lazarczyk, Marta Alicja / Boszczyk, Anna / Samaha, Robert / Grzela, Tomasz

    International journal of molecular medicine

    2006  Volume 17, Issue 1, Page(s) 135–139

    Abstract: Pentoxifylline (PTX) is an unspecific inhibitor of phosphodiesterase activity that increases intracellular concentration of cyclic nucleotides, mainly cAMP. Since PTX improves microcirculatory blood flow, it is commonly and often chronically used in ... ...

    Abstract Pentoxifylline (PTX) is an unspecific inhibitor of phosphodiesterase activity that increases intracellular concentration of cyclic nucleotides, mainly cAMP. Since PTX improves microcirculatory blood flow, it is commonly and often chronically used in peripheral vascular diseases. On the other hand PTX also displays a variety of immunomodulatory activities. PTX inhibits natural cytotoxicity and it has previously been suggested that it could partially act also through its influence on perforin/granzyme-dependent pathways. However, the underlying mechanisms are obscure and it remains unknown whether PTX inhibits natural cytotoxicity influencing only leukocytes or also acting on target cells. In this study, we show that PTX inhibits expression of granzyme A in human leukocytes probably due to suppression of phosphodiesterase activity. Contrary, PTX does not affect expression of granzyme B and H. On the other hand we hypothesized that PTX could inhibit natural cytotoxicity not only affecting leukocytes but also due to generation of resistance to leukocyte-mediated cytotoxicity in target cells e.g. through overexpression of PI-9, a specific granzyme B inhibitor. We found that at the mRNA level, PTX stimulates expression of PI-9 in K562 cells. However, we did not observe such an influence at the protein level, in either K562 cells or in human leukocytes. It may suggest that other PTX-triggered molecular events may interfere with PI-9 overexpression in these cells at the further, post-transcriptional levels. According to these results, PTX did not affect resistance of target cells to natural cytotoxicity. Altogether, PTX inhibits natural cytotoxicity affecting mainly effector but not target cells and in case of the effector cells, besides previously reported mechanisms, it can also inhibit granzyme A expression.
    MeSH term(s) Bucladesine/metabolism ; Granzymes ; Humans ; K562 Cells ; Leukocytes, Mononuclear/cytology ; Leukocytes, Mononuclear/metabolism ; Pentoxifylline/metabolism ; Pertussis Toxin/metabolism ; Phosphodiesterase Inhibitors/metabolism ; Serine Endopeptidases/genetics ; Serine Endopeptidases/metabolism ; Serine Proteinase Inhibitors/metabolism ; Serpins/metabolism
    Chemical Substances Phosphodiesterase Inhibitors ; SERPINB9 protein, human ; Serine Proteinase Inhibitors ; Serpins ; Bucladesine (63X7MBT2LQ) ; Pertussis Toxin (EC 2.4.2.31) ; GZMB protein, human (EC 3.4.21.-) ; GZMH protein, human (EC 3.4.21.-) ; Granzymes (EC 3.4.21.-) ; Serine Endopeptidases (EC 3.4.21.-) ; GZMA protein, human (EC 3.4.21.78) ; Pentoxifylline (SD6QCT3TSU)
    Language English
    Publishing date 2006-01
    Publishing country Greece
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1444428-8
    ISSN 1107-3756
    ISSN 1107-3756
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Differential influence of pentoxifylline on murine colon adenocarcinoma- and melanoma-derived metastatic tumor development in lungs.

    Lazarczyk, Maciej / Grzela, Tomasz / Niderla, Justyna / Lazarczyk, Marta Alicja / Milewski, Lukasz / Dziunycz, Piotr / Skopinski, Piotr / Golab, Jakub

    Oncology reports

    2004  Volume 11, Issue 5, Page(s) 1121–1125

    Abstract: Pentoxifylline (PTX), a methylxanthine derivative, is commonly and in most cases chronically used in patients suffering from peripheral vascular diseases. It increases erythrocyte flexibility, reduces blood viscosity and improves microcirculatory flow. ... ...

    Abstract Pentoxifylline (PTX), a methylxanthine derivative, is commonly and in most cases chronically used in patients suffering from peripheral vascular diseases. It increases erythrocyte flexibility, reduces blood viscosity and improves microcirculatory flow. Moreover, PTX has been found to enhance anticancer activity of some chemotherapeutic agents and ionizing irradiation. On the other hand, PTX has been recently shown to inhibit anticancer response and promote murine tumor growth in liver. In this study we show that PTX facilitates development of murine colon adenocarcinoma- but not melanoma-derived tumors also in lungs. It could suggest that tumor-promoting PTX activity is tissue-independent, although, it might depend on the cancer cell line.
    MeSH term(s) Adenocarcinoma/drug therapy ; Adenocarcinoma/pathology ; Animals ; Colonic Neoplasms/drug therapy ; Colonic Neoplasms/pathology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/secondary ; Melanoma/pathology ; Mice ; Mice, Inbred BALB C ; Pentoxifylline/therapeutic use ; Xenograft Model Antitumor Assays
    Chemical Substances Pentoxifylline (SD6QCT3TSU)
    Language English
    Publishing date 2004-05
    Publishing country Greece
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1222484-4
    ISSN 1791-2431 ; 1021-335X
    ISSN (online) 1791-2431
    ISSN 1021-335X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Influence of pentoxifylline on perforin expression in human PBMC.

    Lazarczyk, Maciej / Grzela, Tomasz / Niderla, Justyna / Dziunycz, Piotr / Milewski, Lukasz / Lazarczyk, Marta Alicja / Samaha, Robert

    International journal of molecular medicine

    2004  Volume 14, Issue 4, Page(s) 725–728

    Abstract: Pentoxifylline (PTX) is a methylxanthine derivative that unspecifically inhibits phosphodiesterase activity and thus, it increases intracellular concentration of cyclic nucleotides. Currently, PTX is commonly and chronically used in peripheral blood ... ...

    Abstract Pentoxifylline (PTX) is a methylxanthine derivative that unspecifically inhibits phosphodiesterase activity and thus, it increases intracellular concentration of cyclic nucleotides. Currently, PTX is commonly and chronically used in peripheral blood vessel diseases. Besides its well-known influence on rheologic properties of blood, PTX has also been found to decrease secretion of some cytokines such as IL-12, TNF and IFN-gamma and thus it could exert immunomodulatory activity. Furthermore, PTX inhibits lymphocyte cytotoxicity affecting the perforin-dependent pathway, both in humans and animals. It has also been shown recently that in some murine models, PTX promotes tumor growth. Such a phenomenon, at least partially, could result from PTX-dependent inhibition of natural cytotoxicity. However, the detailed mechanism of PTX influence on cytotoxic activity in humans has not been established. We hypothesized that PTX-dependent inhibition of natural cytotoxicity could result from decrease in perforin expression. In this study, it was shown that pentoxifylline only moderately inhibits perforin expression at the mRNA level in human peripheral blood mononuclear cells (PBMC), and this effect seems to be independent of intracellular cAMP concentration. On the other hand, PTX did not significantly influence perforin expression at the protein level. These results suggest that in humans, contrary to murine models, inhibition of perforin-dependent natural cytotoxicity through pentoxifylline does not result from changes in perforin production. Presumably, influence of PTX on natural cytotoxicity could be caused by e.g. interference with lymphocyte degranulation. Moreover, also other possibilities, such as PTX influence on conformational changes of perforin molecules and/or its influence on susceptibility of target cells to pore-forming of polyperforins cannot be excluded.
    MeSH term(s) Cells, Cultured ; Gene Expression Regulation/drug effects ; Humans ; Lymphocytes/drug effects ; Lymphocytes/metabolism ; Membrane Glycoproteins/genetics ; Membrane Glycoproteins/metabolism ; Pentoxifylline/pharmacology ; Perforin ; Pore Forming Cytotoxic Proteins ; RNA, Messenger/genetics ; RNA, Messenger/metabolism
    Chemical Substances Membrane Glycoproteins ; Pore Forming Cytotoxic Proteins ; RNA, Messenger ; Perforin (126465-35-8) ; Pentoxifylline (SD6QCT3TSU)
    Language English
    Publishing date 2004-10
    Publishing country Greece
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1444428-8
    ISSN 1107-3756
    ISSN 1107-3756
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top